Zhishuang Gao
Overview
Explore the profile of Zhishuang Gao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
63
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun H, Cui Z, Li C, Gao Z, Xu J, Bian Y, et al.
Adv Sci (Weinh)
. 2024 Jul;
11(34):e2401171.
PMID: 38973363
Ripretinib, a broad-spectrum inhibitor of the KIT and PDGFRA receptor tyrosine kinases, is designated as a fourth-line treatment for gastrointestinal stromal tumor (GIST). It is tailored for patients resistant to...
2.
Bian Y, Xu S, Gao Z, Ding J, Li C, Cui Z, et al.
Cancer Lett
. 2024 Jun;
596:217004.
PMID: 38838765
Long non-coding RNA (lncRNA) is closely related to a variety of human cancers, which may provide huge potential biomarkers for cancer diagnosis and treatment. However, the aberrant expression of most...
3.
TRIM21/USP15 balances ACSL4 stability and the imatinib resistance of gastrointestinal stromal tumors
Cui Z, Sun H, Gao Z, Li C, Xiao T, Bian Y, et al.
Br J Cancer
. 2024 Jan;
130(4):526-541.
PMID: 38182686
Background: Imatinib has become an exceptionally effective targeted drug for treating gastrointestinal stromal tumors (GISTs). Despite its efficacy, the resistance to imatinib is common in GIST patients, posing a significant...
4.
Li C, Gao Z, Cui Z, Liu Z, Bian Y, Sun H, et al.
Oncogene
. 2023 Feb;
42(12):894-910.
PMID: 36725886
Imatinib is a tyrosine kinase inhibitor that is widely used to combat gastrointestinal stromal tumours (GISTs). However, secondary resistance to imatinib is an important challenge in GIST treatment. Recent studies...
5.
Gao Z, Li C, Sun H, Bian Y, Cui Z, Wang N, et al.
Cell Death Differ
. 2022 Dec;
30(2):544-559.
PMID: 36528756
Secondary resistance to imatinib (IM) represents a major challenge for therapy of gastrointestinal stromal tumors (GISTs). Aberrations in oncogenic pathways, including autophagy, correlate with IM resistance. Regulation of autophagy-related protein...
6.
Bian Y, Wang Y, Xu S, Gao Z, Li C, Fan Z, et al.
Cells
. 2022 Oct;
11(19).
PMID: 36230970
Background: Long non-coding RNAs modulate tumor occurrence through different molecular mechanisms. It had been reported that HNF1A-AS1 (HNF1A Antisense RNA 1) was differently expressed in multiple tumors. The role of...
7.
Xu K, Zhang Q, Chen M, Li B, Wang N, Li C, et al.
Cancer Lett
. 2022 Jan;
530:85-99.
PMID: 35032557
N-methyladenosine (mA) is a frequently occurring mRNA modification, which regulates mRNA stability, splicing, and translation. However, its role in drug resistance of gastrointestinal stromal tumor (GIST) is not known. Here,...